2,287 results match your criteria Ca-a Cancer Journal For Clinicians[Journal]


Proximal serrated polyps increase the future risk of colorectal cancer.

Authors:
Mike Fillon

CA Cancer J Clin 2020 Jul 10. Epub 2020 Jul 10.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3322/caac.21625DOI Listing

Human papillomavirus vaccination 2020 guideline update: American Cancer Society guideline adaptation.

CA Cancer J Clin 2020 Jul 8. Epub 2020 Jul 8.

Louisiana State University School of Public Health, New Orleans, Louisiana.

The American Cancer Society (ACS) presents an adaptation of the current Advisory Committee on Immunization Practices recommendations for human papillomavirus (HPV) vaccination. The ACS recommends routine HPV vaccination between ages 9 and 12 years to achieve higher on-time vaccination rates, which will lead to increased numbers of cancers prevented. Health care providers are encouraged to start offering the HPV vaccine series at age 9 or 10 years. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3322/caac.21616DOI Listing

Vaccination for the prevention of human papillomavirus cancers.

Authors:

CA Cancer J Clin 2020 Jul 8. Epub 2020 Jul 8.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3322/caac.21623DOI Listing

Mailed fecal immunochemical test outreach for colorectal cancer screening: Summary of a Centers for Disease Control and Prevention-sponsored summit.

CA Cancer J Clin 2020 Jun 25. Epub 2020 Jun 25.

Department of Internal Medicine and LiveStrong Cancer Institutes, Dell Medical School, University of Texas Austin, Austin, Texas.

Uptake of colorectal cancer screening remains suboptimal. Mailed fecal immunochemical testing (FIT) offers promise for increasing screening rates, but optimal strategies for implementation have not been well synthesized. In June 2019, the Centers for Disease Control and Prevention convened a meeting of subject matter experts and stakeholders to answer key questions regarding mailed FIT implementation in the United States. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3322/caac.21615DOI Listing

American Cancer Society guideline for diet and physical activity for cancer prevention.

CA Cancer J Clin 2020 Jun 9. Epub 2020 Jun 9.

Cancer Control, American Cancer Society, Atlanta, Georgia.

The American Cancer Society (ACS) publishes the Diet and Physical Activity Guideline to serve as a foundation for its communication, policy, and community strategies and, ultimately, to affect dietary and physical activity patterns among Americans. This guideline is developed by a national panel of experts in cancer research, prevention, epidemiology, public health, and policy, and reflects the most current scientific evidence related to dietary and activity patterns and cancer risk. The ACS guideline focuses on recommendations for individual choices regarding diet and physical activity patterns, but those choices occur within a community context that either facilitates or creates barriers to healthy behaviors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3322/caac.21591DOI Listing

A healthy diet and physical activity can help reduce your cancer risk.

Authors:

CA Cancer J Clin 2020 Jun 9. Epub 2020 Jun 9.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3322/caac.21592DOI Listing

Management of glioblastoma: State of the art and future directions.

CA Cancer J Clin 2020 Jun 1. Epub 2020 Jun 1.

The Preston Robert Tisch Brain Tumor Center, Duke University, Durham, North Carolina, USA.

Glioblastoma is the most common malignant primary brain tumor. Overall, the prognosis for patients with this disease is poor, with a median survival of <2 years. There is a slight predominance in males, and incidence increases with age. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3322/caac.21613DOI Listing

Climate change and cancer.

CA Cancer J Clin 2020 May 18. Epub 2020 May 18.

Department of Pediatrics, Boston Children's Hospital, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3322/caac.21610DOI Listing

Improvements Needed in Palliative Care Services.

Authors:
Mike Fillon

CA Cancer J Clin 2020 May 8. Epub 2020 May 8.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3322/caac.21612DOI Listing

Melanoma Threats From Ultraviolet Exposure Vary by State.

Authors:
Mike Fillon

CA Cancer J Clin 2020 May 7. Epub 2020 May 7.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3322/caac.21611DOI Listing

Innovations in research and clinical care using patient-generated health data.

CA Cancer J Clin 2020 May 20;70(3):182-199. Epub 2020 Apr 20.

Department of Radiation Oncology, Moffitt Cancer Center, Tampa, Florida.

Patient-generated health data (PGHD), or health-related data gathered from patients to help address a health concern, are used increasingly in oncology to make regulatory decisions and evaluate quality of care. PGHD include self-reported health and treatment histories, patient-reported outcomes (PROs), and biometric sensor data. Advances in wireless technology, smartphones, and the Internet of Things have facilitated new ways to collect PGHD during clinic visits and in daily life. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3322/caac.21608DOI Listing

Soft-tissue sarcoma in adults: An update on the current state of histiotype-specific management in an era of personalized medicine.

CA Cancer J Clin 2020 May 10;70(3):200-229. Epub 2020 Apr 10.

Division of Surgical Oncology, Winship Cancer Institute, Emory University Hospital Midtown, Atlanta, Georgia.

Soft-tissue sarcomas (STS) are rare tumors that account for 1% of all adult malignancies, with over 100 different histologic subtypes occurring predominately in the trunk, extremity, and retroperitoneum. This low incidence is further complicated by their variable presentation, behavior, and long-term outcomes, which emphasize the importance of centralized care in specialized centers with a multidisciplinary team approach. In the last decade, there has been an effort to improve the quality of care for patients with STS based on anatomic site and histology, and multiple ongoing clinical trials are focusing on tailoring therapy to histologic subtype. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3322/caac.21605DOI Listing

New study links hair chemicals to breast cancer.

Authors:
Mike Fillon

CA Cancer J Clin 2020 May 2;70(3):141-142. Epub 2020 Apr 2.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3322/caac.21602DOI Listing

Genetic factors contribute to subsequent neoplasms in survivors of childhood cancer.

Authors:
Mike Fillon

CA Cancer J Clin 2020 May 2;70(3):143-144. Epub 2020 Apr 2.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3322/caac.21603DOI Listing

The Affordable Care Act and access to care across the cancer control continuum: A review at 10 years.

CA Cancer J Clin 2020 May 23;70(3):165-181. Epub 2020 Mar 23.

Surveillance and Health Services Research, American Cancer Society, Atlanta, Georgia.

Lack of health insurance coverage is strongly associated with poor cancer outcomes in the United States. The uninsured are less likely to have access to timely and effective cancer prevention, screening, diagnosis, treatment, survivorship, and end-of-life care than their counterparts with health insurance coverage. On March 23, 2010, the Patient Protection and Affordable Care Act (ACA) was signed into law, representing the largest change to health care delivery in the United States since the introduction of the Medicare and Medicaid programs in 1965. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3322/caac.21604DOI Listing

Colorectal cancer statistics, 2020.

CA Cancer J Clin 2020 May 5;70(3):145-164. Epub 2020 Mar 5.

Surveillance and Health Services Research, American Cancer Society, Atlanta, Georgia.

Colorectal cancer (CRC) is the second most common cause of cancer death in the United States. Every 3 years, the American Cancer Society provides an update of CRC occurrence based on incidence data (available through 2016) from population-based cancer registries and mortality data (through 2017) from the National Center for Health Statistics. In 2020, approximately 147,950 individuals will be diagnosed with CRC and 53,200 will die from the disease, including 17,930 cases and 3,640 deaths in individuals aged younger than 50 years. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3322/caac.21601DOI Listing

Metastatic melanoma.

CA Cancer J Clin 2020 Mar 26;70(2):78-85. Epub 2020 Feb 26.

Department of Hematology/Oncology, Emory Winship Cancer Institute, Atlanta, Georgia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3322/caac.21599DOI Listing

Introducing the "Virtual Tumor Board" series in CA: A Cancer Journal for Clinicians.

Authors:
Keith A Delman

CA Cancer J Clin 2020 Mar 26;70(2):77. Epub 2020 Feb 26.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3322/caac.21598DOI Listing

Enhancing global access to cancer medicines.

CA Cancer J Clin 2020 Mar 18;70(2):105-124. Epub 2020 Feb 18.

Preclinical Research Program, Vall d'Hebron Institute of Oncology, Barcelona, Spain.

Globally, cancer is the second leading cause of death, with numbers greatly exceeding those for human immunodeficiency virus/acquired immunodeficiency syndrome, tuberculosis, and malaria combined. Limited access to timely diagnosis, to affordable, effective treatment, and to high-quality care are just some of the factors that lead to disparities in cancer survival between countries and within countries. In this article, the authors consider various factors that prevent access to cancer medicines (particularly access to essential cancer medicines). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3322/caac.21597DOI Listing

An overview of precision oncology basket and umbrella trials for clinicians.

CA Cancer J Clin 2020 Mar 7;70(2):125-137. Epub 2020 Feb 7.

Department of Health Research Methodology, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada.

With advancements in biomarkers and momentum in precision medicine, biomarker-guided trials such as basket trials and umbrella trials have been developed under the master protocol framework. A master protocol refers to a single, overarching design developed to evaluate multiple hypotheses with the general goal of improving the efficiency of trial evaluation. One type of master protocol is the basket trial, in which a targeted therapy is evaluated for multiple diseases that share common molecular alterations or risk factors that may help predict whether the patients will respond to the given therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3322/caac.21600DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7187272PMC

Increased radiation intensity found to be safe for the treatment of prostate cancer.

Authors:
Mike Fillon

CA Cancer J Clin 2020 Mar 21;70(2):73-74. Epub 2020 Jan 21.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3322/caac.21595DOI Listing

Exploring the causes of chronic cancer pain and possible remedies.

Authors:
Mike Fillon

CA Cancer J Clin 2020 Mar 21;70(2):75-76. Epub 2020 Jan 21.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3322/caac.21594DOI Listing

A review of cancer immunotherapy toxicity.

CA Cancer J Clin 2020 Mar 16;70(2):86-104. Epub 2020 Jan 16.

Division of Medical Oncology, Duke University, Durham, North Carolina.

Cancer immunotherapies, including checkpoint inhibitors and adoptive cell therapy, manipulate the immune system to recognize and attack cancer cells. These therapies have the potential to induce durable responses in multiple solid and hematologic malignancies and thus have transformed treatment algorithms for numerous tumor types. Cancer immunotherapies lead to unique toxicity profiles distinct from the toxicities of other cancer therapies, depending on their mechanism of action. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3322/caac.21596DOI Listing

Cancer statistics, 2020.

CA Cancer J Clin 2020 Jan 8;70(1):7-30. Epub 2020 Jan 8.

Surveillance and Health Services Research, American Cancer Society, Atlanta, Georgia.

Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths that will occur in the United States and compiles the most recent data on population-based cancer occurrence. Incidence data (through 2016) were collected by the Surveillance, Epidemiology, and End Results Program; the National Program of Cancer Registries; and the North American Association of Central Cancer Registries. Mortality data (through 2017) were collected by the National Center for Health Statistics. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3322/caac.21590DOI Listing
January 2020

The rapidly changing landscape in mature T-cell lymphoma (MTCL) biology and management.

CA Cancer J Clin 2020 Jan 9;70(1):47-70. Epub 2019 Dec 9.

Department of Medicine, Center for Lymphoid Malignancies, Columbia University Medical Center, College of Physicians and Surgeons, New York, New York.

Historical advances in the care of patients with non-Hodgkin lymphoma (NHL) have been restricted largely to patients with B-cell lymphoma. The peripheral T-cell lymphomas (PTCLs), which are rare and heterogeneous in nature, have yet to experience the same degree of improvement in outcome over the past 20 to 30 years. It is estimated that there are approximately 80,000 and 14,000 cases, respectively, of NHL and Hodgkin lymphoma per year in the United States. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3322/caac.21589DOI Listing
January 2020

Immune checkpoint inhibitors may be safe for patients with preexisting autoimmune disease.

Authors:
Mike Fillon

CA Cancer J Clin 2020 Jan 8;70(1):3-4. Epub 2019 Nov 8.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3322/caac.21587DOI Listing
January 2020

Serious kidney injuries may be related to cancer therapies.

Authors:
Mike Fillon

CA Cancer J Clin 2020 Jan 8;70(1):5-6. Epub 2019 Nov 8.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3322/caac.21588DOI Listing
January 2020

Understanding and addressing social determinants to advance cancer health equity in the United States: A blueprint for practice, research, and policy.

CA Cancer J Clin 2020 Jan 29;70(1):31-46. Epub 2019 Oct 29.

Cancer Control Department, American Cancer Society, Atlanta, Georgia.

Although cancer mortality rates declined in the United States in recent decades, some populations experienced little benefit from advances in cancer prevention, early detection, treatment, and survivorship care. In fact, some cancer disparities between populations of low and high socioeconomic status widened during this period. Many potentially preventable cancer deaths continue to occur, and disadvantaged populations bear a disproportionate burden. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3322/caac.21586DOI Listing
January 2020
1 Read

Exercise is medicine in oncology: Engaging clinicians to help patients move through cancer.

CA Cancer J Clin 2019 11 16;69(6):468-484. Epub 2019 Oct 16.

Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland.

Multiple organizations around the world have issued evidence-based exercise guidance for patients with cancer and cancer survivors. Recently, the American College of Sports Medicine has updated its exercise guidance for cancer prevention as well as for the prevention and treatment of a variety of cancer health-related outcomes (eg, fatigue, anxiety, depression, function, and quality of life). Despite these guidelines, the majority of people living with and beyond cancer are not regularly physically active. Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.3322/caac.21579
Publisher Site
http://dx.doi.org/10.3322/caac.21579DOI Listing
November 2019
6 Reads
99.999 Impact Factor

Adolescent and young adult oncology-past, present, and future.

CA Cancer J Clin 2019 11 8;69(6):485-496. Epub 2019 Oct 8.

Division of Hematology/Oncology, University of Pittsburgh Medical Center, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania.

There are nearly 70,000 new cancer diagnoses made annually in adolescents and young adults (AYAs) in the United States. Historically, AYA patients with cancer, aged 15 to 39 years, have not shown the same improved survival as older or younger cohorts. This article reviews the contemporary cancer incidence and survival data through 2015 for the AYA patient population based on the National Cancer Institute's Surveillance, Epidemiology, and End Results registry program and the North American Association of Central Cancer Registries. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3322/caac.21585DOI Listing
November 2019

Breast cancer statistics, 2019.

CA Cancer J Clin 2019 11 2;69(6):438-451. Epub 2019 Oct 2.

Surveillance and Health Services Research, American Cancer Society, Atlanta, Georgia.

This article is the American Cancer Society's biennial update on female breast cancer statistics in the United States, including data on incidence, mortality, survival, and screening. Over the most recent 5-year period (2012-2016), the breast cancer incidence rate increased slightly by 0.3% per year, largely because of rising rates of local stage and hormone receptor-positive disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3322/caac.21583DOI Listing
November 2019
3 Reads

Lung cancer radiation may increase the risk of major adverse cardiac events.

Authors:
Mike Fillon

CA Cancer J Clin 2019 11 23;69(6):435-437. Epub 2019 Sep 23.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3322/caac.21581DOI Listing
November 2019

Multidisciplinary care coupled with targeted muscle reinnervation may reduce pain for amputees.

Authors:
Mike Fillon

CA Cancer J Clin 2019 11 23;69(6):433-434. Epub 2019 Sep 23.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3322/caac.21582DOI Listing
November 2019
1 Read

Cancer statistics for adults aged 85 years and older, 2019.

CA Cancer J Clin 2019 11 7;69(6):452-467. Epub 2019 Aug 7.

Surveillance and Health Services Research, American Cancer Society, Atlanta, Georgia.

Adults aged 85 years and older, the "oldest old," are the fastest-growing age group in the United States, yet relatively little is known about their cancer burden. Combining data from the National Cancer Institute, the North American Association of Central Cancer Registries, and the National Center for Health Statistics, the authors provide comprehensive information on cancer occurrence in adults aged 85 years and older. In 2019, there will be approximately 140,690 cancer cases diagnosed and 103,250 cancer deaths among the oldest old in the United States. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3322/caac.21577DOI Listing
November 2019

Brachytherapy: An overview for clinicians.

CA Cancer J Clin 2019 09 30;69(5):386-401. Epub 2019 Jul 30.

Department of Radiation Oncology, Gustave Roussy Comprehensive Cancer Center, Villejuif, France.

Brachytherapy is a specific form of radiotherapy consisting of the precise placement of radioactive sources directly into or next to the tumor. This technique is indicated for patients affected by various types of cancers. It is an optimal tool for delivering very high doses to the tumor focally while minimizing the probability of normal tissue complications. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3322/caac.21578DOI Listing
September 2019
3 Reads

Tools to facilitate communication during physician-patient consultations in cancer care: An overview of systematic reviews.

CA Cancer J Clin 2019 11 24;69(6):497-520. Epub 2019 Jul 24.

Center for Cancer Research and Department of General Practice, University of Melbourne, Melbourne, Victoria, Australia.

Tools have been developed to facilitate communication and support information exchange between people diagnosed with cancer and their physicians. Patient-reported outcome measures, question prompt lists, patient-held records, tape recordings of consultations, decision aids, and survivorship care plans have all been promoted as potential tools, and there is extensive literature exploring their impact on patient outcomes. Eleven systematic reviews of studies evaluating tools to facilitate patient-physician communication were reviewed and summarized in this overview of systematic reviews. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3322/caac.21573DOI Listing
November 2019
3 Reads

Prostate cancer tool may help patients to decide on treatment.

Authors:
Mike Fillon

CA Cancer J Clin 2019 09 18;69(5):347-348. Epub 2019 Jul 18.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3322/caac.21574DOI Listing
September 2019

Patients with advanced-stage cancer may benefit from telerehabilitation.

Authors:
Mike Fillon

CA Cancer J Clin 2019 09 18;69(5):349-350. Epub 2019 Jul 18.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3322/caac.21575DOI Listing
September 2019

Mesothelioma: Scientific clues for prevention, diagnosis, and therapy.

CA Cancer J Clin 2019 09 8;69(5):402-429. Epub 2019 Jul 8.

Department of Cardiothoracic Surgery, New York University Langone Medical Center, New York, New York.

Mesothelioma affects mostly older individuals who have been occupationally exposed to asbestos. The global mesothelioma incidence and mortality rates are unknown, because data are not available from developing countries that continue to use large amounts of asbestos. The incidence rate of mesothelioma has decreased in Australia, the United States, and Western Europe, where the use of asbestos was banned or strictly regulated in the 1970s and 1980s, demonstrating the value of these preventive measures. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3322/caac.21572DOI Listing
September 2019
7 Reads

Cancer treatment and survivorship statistics, 2019.

CA Cancer J Clin 2019 09 11;69(5):363-385. Epub 2019 Jun 11.

Surveillance Research, American Cancer Society, Atlanta, Georgia.

The number of cancer survivors continues to increase in the United States because of the growth and aging of the population as well as advances in early detection and treatment. To assist the public health community in better serving these individuals, the American Cancer Society and the National Cancer Institute collaborate every 3 years to estimate cancer prevalence in the United States using incidence and survival data from the Surveillance, Epidemiology, and End Results cancer registries; vital statistics from the Centers for Disease Control and Prevention's National Center for Health Statistics; and population projections from the US Census Bureau. Current treatment patterns based on information in the National Cancer Data Base are presented for the most prevalent cancer types. Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.3322/caac.21565
Publisher Site
http://dx.doi.org/10.3322/caac.21565DOI Listing
September 2019
47 Reads

The current state of molecular testing in the treatment of patients with solid tumors, 2019.

CA Cancer J Clin 2019 07 22;69(4):305-343. Epub 2019 May 22.

Professor of Medicine and Oncology, Director, Ruesch Center for the Cure of Gastrointestinal Cancers, Lombardi Comprehensive Cancer Institute, MedStar Georgetown Cancer Institute, Washington, DC.

The world of molecular profiling has undergone revolutionary changes over the last few years as knowledge, technology, and even standard clinical practice have evolved. Broad molecular profiling is now nearly essential for all patients with metastatic solid tumors. New agents have been approved based on molecular testing instead of tumor site of origin. Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.3322/caac.21560
Publisher Site
http://dx.doi.org/10.3322/caac.21560DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6767457PMC
July 2019
10 Reads

Epithelial ovarian cancer: Evolution of management in the era of precision medicine.

CA Cancer J Clin 2019 07 17;69(4):280-304. Epub 2019 May 17.

Chief, Division of Medical Oncology and Hematology; Director, Cancer Clinical Research Unit; and Director, Bras Drug Development Program, Princess Margaret Cancer Centre, University Health Network and Mt. Sinai Health System, Toronto, ON, Canada.

Ovarian cancer is the second most common cause of gynecologic cancer death in women around the world. The outcomes are complicated, because the disease is often diagnosed late and composed of several subtypes with distinct biological and molecular properties (even within the same histological subtype), and there is inconsistency in availability of and access to treatment. Upfront treatment largely relies on debulking surgery to no residual disease and platinum-based chemotherapy, with the addition of antiangiogenic agents in patients who have suboptimally debulked and stage IV disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3322/caac.21559DOI Listing
July 2019
27 Reads

Current recommendations and recent progress in endometrial cancer.

CA Cancer J Clin 2019 07 10;69(4):258-279. Epub 2019 May 10.

Instructor of Medicine, Division of Gynecologic Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.

Endometrial cancer is the most common gynecologic cancer in the United States, and its incidence is rising. Although there have been significant recent advances in our understanding of endometrial cancer biology, many aspects of treatment remain mired in controversy, including the role of surgical lymph node assessment and the selection of patients for adjuvant radiation or chemotherapy. For the subset of women with microsatellite-instable, metastatic disease, anti- programmed cell death protein 1 immunotherapy (pembrolizumab) is now approved by the US Food and Drug Administration, and numerous trials are attempting to build on this early success. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3322/caac.21561DOI Listing
July 2019
3 Reads

The American Cancer Society 2035 challenge goal on cancer mortality reduction.

CA Cancer J Clin 2019 09 8;69(5):351-362. Epub 2019 May 8.

Chief Medical Officer (Former), American Cancer Society, Atlanta, GA.

A summary evaluation of the 2015 American Cancer Society (ACS) challenge goal showed that overall US mortality from all cancers combined declined 26% over the period from 1990 to 2015. Recent research suggests that US cancer mortality can still be lowered considerably by applying known interventions broadly and equitably. The ACS Board of Directors, therefore, commissioned ACS researchers to determine challenge goals for reductions in cancer mortality by 2035. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3322/caac.21564DOI Listing
September 2019
5 Reads

Greater support and resources needed for cancer survivors returning to work.

Authors:
Mike Fillon

CA Cancer J Clin 2019 07 26;69(4):253-255. Epub 2019 Apr 26.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3322/caac.21562DOI Listing

Many primary care providers believe they are ill-prepared for talks with patients with breast cancer.

Authors:
Mike Fillon

CA Cancer J Clin 2019 07 26;69(4):256-257. Epub 2019 Apr 26.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3322/caac.21563DOI Listing
July 2019
1 Read

Cancer screening in the United States, 2019: A review of current American Cancer Society guidelines and current issues in cancer screening.

CA Cancer J Clin 2019 05 15;69(3):184-210. Epub 2019 Mar 15.

Chief Cancer Control Officer, American Cancer Society, Atlanta, GA.

Each year, the American Cancer Society publishes a summary of its guidelines for early cancer detection, data and trends in cancer screening rates, and select issues related to cancer screening. In this issue of the journal, the current American Cancer Society cancer screening guidelines are summarized, and the most current data from the National Health Interview Survey are provided on the utilization of cancer screening for men and women and on the adherence of men and women to multiple recommended screening tests. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3322/caac.21557DOI Listing
May 2019
21 Reads

Study aims to improve colorectal cancer screening rates.

Authors:
Mike Fillon

CA Cancer J Clin 2019 05 12;69(3):161-163. Epub 2019 Mar 12.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.3322/caac.21472
Publisher Site
http://dx.doi.org/10.3322/caac.21472DOI Listing
May 2019
13 Reads

Study evaluates mobile telephone interventions for socioeconomically disadvantaged smokers.

Authors:
Mike Fillon

CA Cancer J Clin 2019 05 11;69(3):164-165. Epub 2019 Mar 11.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3322/caac.21473DOI Listing
May 2019
1 Read

Implementing personalized pathways for cancer follow-up care in the United States: Proceedings from an American Cancer Society-American Society of Clinical Oncology summit.

CA Cancer J Clin 2019 05 8;69(3):234-247. Epub 2019 Mar 8.

Associate Professor, Department of Pediatrics, and Medical Director, Childhood Cancer Survivor Center, The University of Chicago Comer Children's Hospital, Chicago, IL.

A new approach to cancer follow-up care is necessary to meet the needs of cancer survivors while dealing with increasing volume and provider shortages, knowledge gaps, and costs to both health care systems and patients. An approach that triages patients to personalized follow-up care pathways, depending on the type(s) and level(s) of resources needed for patients' long-term care, is in use in the United Kingdom and other countries and has been shown to meet patients' needs, more efficiently use the health care system, and reduce costs. Recognizing that testing and implementing a similar personalized approach to cancer follow-up care in the United States will require a multipronged strategy, the American Cancer Society and the American Society of Clinical Oncology convened a summit in January 2018 to identify the needed steps to move this work from concept to implementation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3322/caac.21558DOI Listing
May 2019
5 Reads